Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration
NCT ID: NCT00150371
Last Updated: 2021-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1100 participants
INTERVENTIONAL
2004-06-30
2005-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
NCT00644670
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
NCT00644709
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
NCT00442845
A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol
NCT00645151
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
NCT00442325
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Triglyceride level 6.8 mmol/L at screening
* LDL-C of 5.7 mmol/L at screening
Exclusion Criteria
* Subjects whose blood cholesterol levels are controlled (LDL-C targets) with statins other than atorvastatin
* Subjects receiving statin doses higher than the following: 10-40mg for simvastatin , 20-40mg for fluvastatin, pravastatin and lovastatin and 10-20 mg for rosuvastatin. Subjects already treated with atorvastatin at the time of screening are not eligible unless atorvastatin has been discontinued at least 2 months prior to screening
* Subjects receiving 2 or more lipid lowering agents are excluded (statins + resins or fibrates or niacin or fish oils)
30 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Coquitlam, British Columbia, Canada
Pfizer Investigational Site
Coquitlam, British Columbia, Canada
Pfizer Investigational Site
Kelowna, British Columbia, Canada
Pfizer Investigational Site
Langley, British Columbia, Canada
Pfizer Investigational Site
Surrey, British Columbia, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Moncton, New Brunswick, Canada
Pfizer Investigational Site
Rothesay, New Brunswick, Canada
Pfizer Investigational Site
Saint John, New Brunswick, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Halifax, B3K 5R3, Nova Scotia, Canada
Pfizer Investigational Site
Brampton, Ontario, Canada
Pfizer Investigational Site
Burlington, Ontario, Canada
Pfizer Investigational Site
Courtice, Ontario, Canada
Pfizer Investigational Site
Downsview, Ontario, Canada
Pfizer Investigational Site
Fort Erie, Ontario, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Hawkesbury, Ontario, Canada
Pfizer Investigational Site
Kitchener, Ontario, Canada
Pfizer Investigational Site
Lindsay, Ontario, Canada
Pfizer Investigational Site
Markham, Ontario, Canada
Pfizer Investigational Site
Midland, Ontario, Canada
Pfizer Investigational Site
Napanee, Ontario, Canada
Pfizer Investigational Site
Newmarket, Ontario, Canada
Pfizer Investigational Site
Niagara Falls, Ontario, Canada
Pfizer Investigational Site
North Bay, Ontario, Canada
Pfizer Investigational Site
North York, Ontario, Canada
Pfizer Investigational Site
Oshawa, Ontario, Canada
Pfizer Investigational Site
Oshawa, Ontario, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Saint Catherines, Ontario, Canada
Pfizer Investigational Site
Saint Catherines, Ontario, Canada
Pfizer Investigational Site
Sarnia, Ontario, Canada
Pfizer Investigational Site
Thornhill, Ontario, Canada
Pfizer Investigational Site
Thunder Bay, Ontario, Canada
Pfizer Investigational Site
Thunder Bay, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Windsor, Ontario, Canada
Pfizer Investigational Site
Charlottetown, Prince Edward Island, Canada
Pfizer Investigational Site
Montague, Prince Edward Island, Canada
Pfizer Investigational Site
Amos, Quebec, Canada
Pfizer Investigational Site
Chicoutimi, Quebec, Canada
Pfizer Investigational Site
Cowansville, Quebec, Canada
Pfizer Investigational Site
Greenfield Park, Quebec, Canada
Pfizer Investigational Site
Greenfield Park, Quebec, Canada
Pfizer Investigational Site
Greenfield Park, Quebec, Canada
Pfizer Investigational Site
Laval, Quebec, Canada
Pfizer Investigational Site
Laval, Quebec, Canada
Pfizer Investigational Site
Laval, Quebec, Canada
Pfizer Investigational Site
Le Gardeur, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Plessisville, Quebec, Canada
Pfizer Investigational Site
Québec, Quebec, Canada
Pfizer Investigational Site
Saint-Eustache, Quebec, Canada
Pfizer Investigational Site
Saint-Léonard, Quebec, Canada
Pfizer Investigational Site
Salaberry Du Valleyfield, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Ste. Foy, Quebec, Canada
Pfizer Investigational Site
Vaudreuil, Quebec, Canada
Pfizer Investigational Site
Regina, Saskatchewan, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
St. John's, , Canada
Pfizer Investigational Site
St. John's, , Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ur E, Langer A, Rabkin SW, Calciu CD, Leiter LA; CanACTFAST Study Investigators. Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study. Can J Cardiol. 2010 Feb;26(2):80-6. doi: 10.1016/s0828-282x(10)70003-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581091
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.